THOMAS MONATH to Antibodies, Neutralizing
This is a "connection" page, showing publications THOMAS MONATH has written about Antibodies, Neutralizing.
Connection Strength
1.469
-
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
Score: 0.284
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
Score: 0.183
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
Score: 0.172
-
Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease. Front Immunol. 2023; 14:1216225.
Score: 0.165
-
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022 05 16; 132(10).
Score: 0.151
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
Score: 0.084
-
An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
Score: 0.070
-
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
Score: 0.065
-
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg Microbes Infect. 2022 Dec; 11(1):2724-2734.
Score: 0.039
-
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. J Infect Dis. 2022 10 17; 226(8):1401-1406.
Score: 0.039
-
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
Score: 0.039
-
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. J Infect Dis. 2022 04 19; 225(8):1399-1410.
Score: 0.038
-
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
Score: 0.034
-
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
Score: 0.027
-
Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
Score: 0.027
-
Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector. Clin Vaccine Immunol. 2017 Jan; 24(1).
Score: 0.026
-
Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016 Apr 12; 34(17):1993-9.
Score: 0.025